There is NO current big pharma solution for regenerating cartilage, bone and nerve stem cells, Biotime has all three. Best long term stock in stem sector.
Agreed! $2.70 is a good deal with PanC-DX right around the corner. The future market demand for cancer test products are big especially since current products are archaic. Big pharma tests on the market are too slow, not accurate enough and expensive. Biotime's on the contrary are fast(blood and urine), cheap and accurate.
If PanC-DX is successful as last reports indicate, BTX(OncoCyte) will take huge piece of the cancer diagnostic pie. Weil Cornel, John Hopkins, and GE partnerships also help!
Revenues will be huge
Medical partners John Hopkins and Weil Cornell
Good insight, amazing all that has gotten done in eight years with no revenues, just goes to show how much investors and partners believe in this company.
Proof is in the partners:
CORPORATE PARTNERSHIPS & LICENSING
GE Healthcare (December 2014) »
Abcodia Ltd. (September 2014) »
Cancer Research UK (September 2014) »
University of Wisconsin and Louvain University (August 2014) »
Cornell University (May 2014) »
California Institute of Regenerative Medicine (May 2014) »
Jade Therapeutics (September 2013) »
University of California, Los Angeles (April 2013) »
Wistar Institute (January 2012) »
USCN Life Science, Inc. (December 2011) »
Cornell University (September 2011) »
California Institute of Regenerative Medicine (November 2010) »
Teva Pharmaceutical Industries, Ltd. (October 2010) »
Millipore (July 2009) »
Ocata Therapeutics, Inc. (formerly Advanced Cell Technology, Inc.) (July 2008) »
Wisconsin Alumni Research Foundation (January 2008) »
Hospira, Inc. (U.S.) / CJ Health Corporation (December 2006) »
CJ Health Corporation (April 2003) »
Abbott Laboratories, Inc. (April 1997) »
Good insight, amazing all that has gotten done in eight years with no revenues, just goes to show how much investors and partners believe!
PHILADELPHIA & ALAMEDA, Calif.--(BUSINESS WIRE)--
The Wistar Institute and BioTime, Inc. (NYSE MKT: BTX) announced that Wistar and BioTime’s subsidiary OncoCyte Corporation, have expanded their collaborative relationship to develop a simple, non-invasive, blood-based test designed to aid physicians in the early detection of lung cancer. This expanded collaboration follows earlier clinical trials, the interim results of which were presented at the May 2015 American Thoracic Society (ATS) International Conference. Wistar is an international biomedical research leader in cancer, immunology and infectious diseases. OncoCyte is a developer of novel, non-invasive liquid biopsy products for the early detection of cancer.
Btw, June 24 will have BTX subsidiary ESI present GE product update.
GE/BTX partnership announced bacK in Dec, stem cell drug testing kits likely to be covered on June 24th presentation, if so expect nice move upwards.
Have doubled over last year, 4th quarter triple coming as PanC-DX to be released to market along with drug testing/GE kits and Renevia for reconstructive surgery in EU. Talking billions in revenue. BTX best kept secret, but not for long.
Bump...let's keep things in perspective. PanC-DX bladder and lung positive results, cancer diagnostic products on track for 4th Q release.
BioTime, Inc. (NYSE MKT: BTX) today announced that Chief Executive Officer Michael D. West, PhD will present at the Jefferies 2015 Global Healthcare Conference to be held in New York on June 1-4, 2015. Dr. West will provide an overview of the company and an update on product development in his presentation at 3:00 PM EDT on Wednesday, June 3, 2015.